<DOC>
	<DOCNO>NCT01179048</DOCNO>
	<brief_summary>This trial conduct Africa , Asia , Europe , North South America . The aim trial determine long term effect liraglutide cardiovascular event subject type 2 diabetes .</brief_summary>
	<brief_title>Liraglutide Effect Action Diabetes : Evaluation Cardiovascular Outcome Results</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Liraglutide</mesh_term>
	<criteria>Type 2 diabetes Age min . 50 year screen concomitant cardiovascular , cerebrovascular peripheral vascular disease chronic renal failure chronic heart failure OR age min . 60 year screen specify risk factor cardiovascular disease HbA1c : 7.0 % Antidiabetic drug naive treat one oral antidiabetic drug ( OADs ) treat human NPH insulin longacting insulin analogue premixed insulin , alone combination OAD ( ) Type 1 diabetes Use glucagonlike peptide1 ( GLP1 ) receptor agonist ( exenatide , liraglutide ) pramlintide dipeptidyl peptidase 4 ( DPP4 ) inhibitor within 3 month prior screen ( trial start ) Use insulin human NPH insulin longacting insulin analogue premixed insulin within 3 month prior screen . Shortterm use insulin period connection intercurrent illness allow , Investigator 's discretion</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
</DOC>